Demcon Hemics
Latest round
- Series B
Last raised
- Jan 2015
Total raised
- Undisclosed
Investors
- 4
About Demcon Hemics
Founded in 2011 in the Netherlands, Demcon Hemics BV specializes in medical device technology aimed at diagnosing and managing Rheumatoid Arthritis. The company has not undergone any significant pivots or changes since its inception. It was established independently and not as a subsidiary or through a merger.Demcon Hemics specializes in developing innovative medical devices for the assessment and management of Rheumatoid Arthritis (RA). The company's flagship product, the HandScan, utilizes patented Optical Inflammation Detection technology to provide non-invasive, rapid, and objective quantification of inflammation levels in the joints of the hands and wrists. By applying a pressure cuff to induce blood pooling, the device differentiates between inflamed and healthy tissues using red and near-infrared light to measure changes in light transmission. This process generates a 2D image that visualizes vascular responses, thereby aiding rheumatologists in effectively monitoring disease activity and guiding treatment plans.Hemics operates under a transactional model that incorporates direct sales to healthcare providers and institutions that utilize its medical imaging technology. The company engages in B2B transactions, providing its HandScan devices to hospitals and clinics, which can integrate the technology into their existing healthcare systems. Revenue is generated through the sale of the HandScan units, and potentially through service agreements that may include maintenance and support options for these devices. The pricing structure for these devices reflects their advanced technology and clinical utility, positioning them as essential tools for rheumatologists seeking effective methods to monitor and treat RA.Demcon Hemics BV is focused on expanding its product offerings and market reach. The company plans to introduce new products that enhance the capabilities of the HandScan technology in the upcoming years. Additionally, Hemics is targeting expansion into new geographic regions, particularly in emerging markets throughout Europe and North America, by the end of 2024.050 mn from EASME will be utilized to support product development and market entry strategies, enabling the company to further its mission of providing innovative solutions for Rheumatoid Arthritis management.
Who invested in Demcon Hemics
4 investors across 2 rounds
See all investors in Demcon Hemics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Demcon Hemics
Who invested in Demcon Hemics?
Demcon Hemics has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Demcon Hemics raised?
Demcon Hemics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Demcon Hemics last raise money?
Demcon Hemics's most recent round on record is a Series B, in Jan 2015.
What does Demcon Hemics do?
Founded in 2011 in the Netherlands, Demcon Hemics BV specializes in medical device technology aimed at diagnosing and managing Rheumatoid Arthritis.
Where is Demcon Hemics headquartered?
Demcon Hemics is headquartered in Netherlands.
Which VCs invest in companies like Demcon Hemics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back medical devices & equipment companies at Demcon Hemics's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series B
Raising like Demcon Hemics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.